Therefore, the crucial role of the PI3K/AKT/mTOR pathway in GSC survival, proliferation, and resistance makes it a highly attractive therapeutic target for combating glioblastoma aggressiveness and recurrence. This evidence concerns the gene AKT1 and glioblastoma.